218 related articles for article (PubMed ID: 30935343)
21. Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.
Markovic U; Bulla A; Leotta S; Stella S; Consoli ML; TambÈ L; Conticello C; DI Raimondo F; Stagno F
Anticancer Res; 2020 Sep; 40(9):5313-5317. PubMed ID: 32878823
[TBL] [Abstract][Full Text] [Related]
22. Gelatinous bone marrow transformation and emergence of clonal Philadelphia-negative cytogenetic abnormalities with excess blasts in a patient with chronic myeloid leukemia treated with dasatinib.
Hermel DJ; Nael A; Lu YT; Kim J; Brynes RK; Vergara-Lluri M; Akhtari M
Anticancer Drugs; 2019 Apr; 30(4):416-421. PubMed ID: 30875349
[TBL] [Abstract][Full Text] [Related]
23. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
Xu Y; Wahner AE; Nguyen PL
Arch Pathol Lab Med; 2004 Sep; 128(9):980-5. PubMed ID: 15338554
[TBL] [Abstract][Full Text] [Related]
24. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
25. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
[TBL] [Abstract][Full Text] [Related]
26. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
27. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
28. A Case Report of Chronic Myelogenous Leukemia Presenting as Blastic Crisis with a T-Cell Acute Lymphoblastic Leukemia Phenotype: Awareness of a Rare Entity.
Efstathopoulou M; Zoi K; Siakantaris MP; Koumbi D; Zannou A; Triantafyllou EF; Tsourouflis G; Lakiotaki E; Vassilakopoulos TP; Angelopoulou MK
Acta Haematol; 2023; 146(6):530-537. PubMed ID: 37557081
[TBL] [Abstract][Full Text] [Related]
29. Uncommon karyotypic abnormality, t(11;19)(q23;p13.3), in a patient with blastic phase of chronic myeloid leukemia.
Suzuki K; Sugawara T; Kowata S; Utsugizawa T; Ito S; Murai K; Ishida Y
Cancer Genet Cytogenet; 2004 Apr; 150(2):159-63. PubMed ID: 15066325
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
Maiti A; Franquiz MJ; Ravandi F; Cortes JE; Jabbour EJ; Sasaki K; Marx K; Daver NG; Kadia TM; Konopleva MY; Masarova L; Borthakur G; DiNardo CD; Naqvi K; Pierce S; Kantarjian HM; Short NJ
Acta Haematol; 2020; 143(6):567-573. PubMed ID: 32289808
[TBL] [Abstract][Full Text] [Related]
31. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
Jabbour E; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
Quintás-Cardama A; Kantarjian H; Shan J; Jabbour E; Abruzzo LV; Verstovsek S; Garcia-Manero G; O'Brien S; Cortes J
Cancer; 2011 Nov; 117(22):5085-93. PubMed ID: 21523765
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.
Miura M
Biol Pharm Bull; 2015; 38(5):645-54. PubMed ID: 25947908
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
Li J; Xu G; Yu S; He L; Guo L
J Int Med Res; 2011; 39(2):337-47. PubMed ID: 21672337
[TBL] [Abstract][Full Text] [Related]
35. [Cytogenetic and clinical features of Philadelphia chromosome positive leukemias].
Becher R; Kloke O
Verh Dtsch Ges Pathol; 1990; 74():36-42. PubMed ID: 1708614
[TBL] [Abstract][Full Text] [Related]
36. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
37. Chromosomal aberrations during progression of chronic myeloid leukemia identified by cytogenetic and molecular cytogenetic tools: implication of 1q12-21.
Su XY; Wong N; Cao Q; Yu LZ; Niu C; Wickham N; Johnson PJ; Chen Z; Chen SJ
Cancer Genet Cytogenet; 1999 Jan; 108(1):6-12. PubMed ID: 9973917
[TBL] [Abstract][Full Text] [Related]
38. [Chronic Myelogenous Leukemia].
Hochhaus A; Eigendorff E; Ernst T
Dtsch Med Wochenschr; 2018 Sep; 143(18):1304-1310. PubMed ID: 30199910
[TBL] [Abstract][Full Text] [Related]
39. Optimal Response in a Patient With CML Expressing
Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
[TBL] [Abstract][Full Text] [Related]
40. Isolated Central Nervous System Blast Crisis of Chronic Myeloid Leukemia with Dasatinib Therapy.
Dong Y; Wang J; Shen Y; Zhang Q; Zhai Z; Tao Q
Clin Lab; 2021 Feb; 67(2):. PubMed ID: 33616329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
